A genetic test known as chromosomal microarray analysis (CMA) could help identify the cause of sudden infant death syndrome (SIDS) or its counterpart in older children, known as sudden unexplained ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...
A genetic test known as chromosomal microarray analysis (CMA) could help identify the cause of sudden infant death syndrome (SIDS) or its counterpart in older children, known as sudden unexplained ...
The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid ...
16d
Helix Launches Whole Exome+® Sequencing for Patients with Rare and Unexplained Genetic Conditions
Helix, the leading enterprise genomics platform, today announced the availability of Whole Exome+® Sequencing (WES+), a comprehensive diagnostic sequencing test now available to ordering providers ...
Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
Thermo Fisher Scientific, Inc. TMO recently launched the Applied Biosystems CytoScan HD Accel array — a new chromosomal microarray intended to enhance cytogenetic research lab productivity, efficiency ...
Introducing the new CytoScan HD Accel microarray that significantly improves the power and speed of genome-wide copy number analysis using industry-leading Chromosomal Microarray (CMA). The highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results